CH647869A5 - Verfahren zur bestimmung eines freien chemischen stoffes. - Google Patents

Verfahren zur bestimmung eines freien chemischen stoffes. Download PDF

Info

Publication number: CH647869A5
Authority: CH; Switzerland
Prior art keywords: substance; antibody; analog; microcapsules; sample
Prior art date: 1978-06-20

Application number

CH5723/79A

Other languages

German (de)

English (en)

Inventor

Robert J Buehler

Theresa H Chan

Franklin Lim

Richard D Moss

Original Assignee

Damon Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1978-06-20

Filing date

1979-06-19

Publication date

1985-02-15

1978-11-27 Priority claimed from US05/963,932 external-priority patent/US4255411A/en

1979-06-19 Application filed by Damon Corp filed Critical Damon Corp

1985-02-15 Publication of CH647869A5 publication Critical patent/CH647869A5/de

Links

239000000126 substance Substances 0.000 title claims description 85
238000000034 method Methods 0.000 title claims description 54
238000012360 testing method Methods 0.000 claims description 55
239000003094 microcapsule Substances 0.000 claims description 54
LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 claims description 51
229960005156 digoxin Drugs 0.000 claims description 51
LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 claims description 51
LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical group C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 claims description 50
108090000623 proteins and genes Proteins 0.000 claims description 29
102000004169 proteins and genes Human genes 0.000 claims description 29
239000000463 material Substances 0.000 claims description 24
239000012528 membrane Substances 0.000 claims description 24
XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 claims description 16
XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 claims description 14
238000006243 chemical reaction Methods 0.000 claims description 14
229940034208 thyroxine Drugs 0.000 claims description 14
230000027455 binding Effects 0.000 claims description 10
238000011088 calibration curve Methods 0.000 claims description 10
239000003153 chemical reaction reagent Substances 0.000 claims description 9
230000000295 complement effect Effects 0.000 claims description 8
238000000926 separation method Methods 0.000 claims description 7
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims description 6
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 6
230000035699 permeability Effects 0.000 claims description 6
229920002873 Polyethylenimine Polymers 0.000 claims description 4
108010071390 Serum Albumin Proteins 0.000 claims description 3
102000007562 Serum Albumin Human genes 0.000 claims description 3
AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical group IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 claims description 3
229960000890 hydrocortisone Drugs 0.000 claims description 3
230000002285 radioactive effect Effects 0.000 claims description 3
229960003604 testosterone Drugs 0.000 claims description 3
230000008859 change Effects 0.000 claims description 2
239000003795 chemical substances by application Substances 0.000 claims 2
239000000376 reactant Substances 0.000 claims 2
XUIIKFGFIJCVMT-LBPRGKRZSA-N L-thyroxine Chemical group IC1=CC(C[C@H]([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-LBPRGKRZSA-N 0.000 claims 1
229950008325 levothyroxine Drugs 0.000 claims 1
239000000243 solution Substances 0.000 description 42
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 36
229940088597 hormone Drugs 0.000 description 36
239000005556 hormone Substances 0.000 description 36
239000000523 sample Substances 0.000 description 27
239000011521 glass Substances 0.000 description 26
238000003756 stirring Methods 0.000 description 19
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 17
LXEJRKJRKIFVNY-UHFFFAOYSA-N terephthaloyl chloride Chemical compound ClC(=O)C1=CC=C(C(Cl)=O)C=C1 LXEJRKJRKIFVNY-UHFFFAOYSA-N 0.000 description 16
239000002775 capsule Substances 0.000 description 15
239000007788 liquid Substances 0.000 description 15
239000012071 phase Substances 0.000 description 14
108091003079 Bovine Serum Albumin Proteins 0.000 description 13
XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 13
229940098773 bovine serum albumin Drugs 0.000 description 13
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 13
239000002953 phosphate buffered saline Substances 0.000 description 13
239000006228 supernatant Substances 0.000 description 13
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 12
239000000178 monomer Substances 0.000 description 12
230000002163 immunogen Effects 0.000 description 11
238000011534 incubation Methods 0.000 description 11
238000002156 mixing Methods 0.000 description 11
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
210000002966 serum Anatomy 0.000 description 10
229910019142 PO4 Inorganic materials 0.000 description 9
239000000203 mixture Substances 0.000 description 9
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 9
239000010452 phosphate Substances 0.000 description 9
241000894007 species Species 0.000 description 9
238000010998 test method Methods 0.000 description 9
238000000502 dialysis Methods 0.000 description 8
-1 fatty acid ester Chemical class 0.000 description 8
SYECJBOWSGTPLU-UHFFFAOYSA-N hexane-1,1-diamine Chemical compound CCCCCC(N)N SYECJBOWSGTPLU-UHFFFAOYSA-N 0.000 description 8
239000002904 solvent Substances 0.000 description 8
229920001213 Polysorbate 20 Polymers 0.000 description 7
238000006116 polymerization reaction Methods 0.000 description 7
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 7
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 7
239000011780 sodium chloride Substances 0.000 description 7
238000002474 experimental method Methods 0.000 description 6
235000017557 sodium bicarbonate Nutrition 0.000 description 6
229910000030 sodium bicarbonate Inorganic materials 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 5
PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 5
150000001875 compounds Chemical class 0.000 description 5
239000003517 fume Substances 0.000 description 5
238000005259 measurement Methods 0.000 description 5
229920000036 polyvinylpyrrolidone Polymers 0.000 description 5
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 5
238000003127 radioimmunoassay Methods 0.000 description 5
239000007790 solid phase Substances 0.000 description 5
238000005406 washing Methods 0.000 description 5
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
239000004698 Polyethylene Substances 0.000 description 4
239000007853 buffer solution Substances 0.000 description 4
238000005119 centrifugation Methods 0.000 description 4
ZYZWOSIRFVIBRH-UHFFFAOYSA-N chloroform;cyclohexane Chemical compound ClC(Cl)Cl.C1CCCCC1 ZYZWOSIRFVIBRH-UHFFFAOYSA-N 0.000 description 4
230000000052 comparative effect Effects 0.000 description 4
229920000573 polyethylene Polymers 0.000 description 4
229920000642 polymer Polymers 0.000 description 4
239000000725 suspension Substances 0.000 description 4
230000007423 decrease Effects 0.000 description 3
238000009792 diffusion process Methods 0.000 description 3
NAQMVNRVTILPCV-UHFFFAOYSA-N hexane-1,6-diamine Chemical compound NCCCCCCN NAQMVNRVTILPCV-UHFFFAOYSA-N 0.000 description 3
239000007791 liquid phase Substances 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
239000001267 polyvinylpyrrolidone Substances 0.000 description 3
239000008213 purified water Substances 0.000 description 3
238000011084 recovery Methods 0.000 description 3
229940036555 thyroid hormone Drugs 0.000 description 3
239000005495 thyroid hormone Substances 0.000 description 3
102000014914 Carrier Proteins Human genes 0.000 description 2
102000006395 Globulins Human genes 0.000 description 2
108010044091 Globulins Proteins 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
239000004952 Polyamide Substances 0.000 description 2
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
102000002248 Thyroxine-Binding Globulin Human genes 0.000 description 2
108010000259 Thyroxine-Binding Globulin Proteins 0.000 description 2
239000012620 biological material Substances 0.000 description 2
229910002092 carbon dioxide Inorganic materials 0.000 description 2
ACWOEBLNSPFLBG-UHFFFAOYSA-N carbonic acid;hexane-1,1-diamine Chemical compound OC(O)=O.CCCCCC(N)N ACWOEBLNSPFLBG-UHFFFAOYSA-N 0.000 description 2
URYUEMMCHKMUAG-UHFFFAOYSA-N carbonic acid;hexane-1,6-diamine Chemical compound OC(O)=O.NCCCCCCN URYUEMMCHKMUAG-UHFFFAOYSA-N 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
230000009137 competitive binding Effects 0.000 description 2
230000009260 cross reactivity Effects 0.000 description 2
235000014113 dietary fatty acids Nutrition 0.000 description 2
239000012153 distilled water Substances 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000003814 drug Substances 0.000 description 2
230000000694 effects Effects 0.000 description 2
239000003995 emulsifying agent Substances 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
239000000194 fatty acid Substances 0.000 description 2
229930195729 fatty acid Natural products 0.000 description 2
230000002452 interceptive effect Effects 0.000 description 2
238000002372 labelling Methods 0.000 description 2
229920002647 polyamide Polymers 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
238000003908 quality control method Methods 0.000 description 2
230000035484 reaction time Effects 0.000 description 2
229920006395 saturated elastomer Polymers 0.000 description 2
238000004062 sedimentation Methods 0.000 description 2
239000010421 standard material Substances 0.000 description 2
239000003270 steroid hormone Substances 0.000 description 2
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
101150072531 10 gene Proteins 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
102000004506 Blood Proteins Human genes 0.000 description 1
108010017384 Blood Proteins Proteins 0.000 description 1
108010078791 Carrier Proteins Proteins 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
WDJUZGPOPHTGOT-OAXVISGBSA-N Digitoxin Natural products O([C@H]1[C@@H](C)O[C@@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@@](C)([C@H](C6=CC(=O)OC6)CC5)CC4)CC3)CC2)C[C@H]1O)[C@H]1O[C@@H](C)[C@H](O[C@H]2O[C@@H](C)[C@@H](O)[C@@H](O)C2)[C@@H](O)C1 WDJUZGPOPHTGOT-OAXVISGBSA-N 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
229920002274 Nalgene Polymers 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
108010071690 Prealbumin Proteins 0.000 description 1
102000007584 Prealbumin Human genes 0.000 description 1
239000013543 active substance Substances 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
210000004100 adrenal gland Anatomy 0.000 description 1
238000010171 animal model Methods 0.000 description 1
239000003125 aqueous solvent Substances 0.000 description 1
239000007982 barbital buffer Substances 0.000 description 1
239000011324 bead Substances 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
108091008324 binding proteins Proteins 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
239000012496 blank sample Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
238000007664 blowing Methods 0.000 description 1
239000001045 blue dye Substances 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
OQNGCCWBHLEQFN-UHFFFAOYSA-N chloroform;hexane Chemical compound ClC(Cl)Cl.CCCCCC OQNGCCWBHLEQFN-UHFFFAOYSA-N 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
230000002950 deficient Effects 0.000 description 1
CZWCKYRVOZZJNM-USOAJAOKSA-N dehydroepiandrosterone sulfate Chemical compound C1[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 CZWCKYRVOZZJNM-USOAJAOKSA-N 0.000 description 1
239000008367 deionised water Substances 0.000 description 1
229910021641 deionized water Inorganic materials 0.000 description 1
150000004985 diamines Chemical class 0.000 description 1
229940061607 dibasic sodium phosphate Drugs 0.000 description 1
229960000648 digitoxin Drugs 0.000 description 1
WDJUZGPOPHTGOT-XUDUSOBPSA-N digitoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)CC5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O WDJUZGPOPHTGOT-XUDUSOBPSA-N 0.000 description 1
238000007865 diluting Methods 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
238000009826 distribution Methods 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000000945 filler Substances 0.000 description 1
238000011049 filling Methods 0.000 description 1
239000012530 fluid Substances 0.000 description 1
230000008014 freezing Effects 0.000 description 1
238000007710 freezing Methods 0.000 description 1
230000006870 function Effects 0.000 description 1
239000007789 gas Substances 0.000 description 1
210000004907 gland Anatomy 0.000 description 1
150000004820 halides Chemical class 0.000 description 1
210000002837 heart atrium Anatomy 0.000 description 1
102000036124 hormone binding proteins Human genes 0.000 description 1
108091011044 hormone binding proteins Proteins 0.000 description 1
239000012535 impurity Substances 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
LPMXVESGRSUGHW-HBYQJFLCSA-N ouabain Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)C[C@@H](O)[C@@H]3[C@@]2(CO)[C@H](O)C1 LPMXVESGRSUGHW-HBYQJFLCSA-N 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000008447 perception Effects 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
239000008055 phosphate buffer solution Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
239000004033 plastic Substances 0.000 description 1
238000006068 polycondensation reaction Methods 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229950009829 prasterone sulfate Drugs 0.000 description 1
239000000047 product Substances 0.000 description 1
239000000186 progesterone Substances 0.000 description 1
229960003387 progesterone Drugs 0.000 description 1
230000005855 radiation Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
238000011076 safety test Methods 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
239000012086 standard solution Substances 0.000 description 1
238000003860 storage Methods 0.000 description 1
210000001550 testis Anatomy 0.000 description 1
210000001685 thyroid gland Anatomy 0.000 description 1
229940035722 triiodothyronine Drugs 0.000 description 1
239000002699 waste material Substances 0.000 description 1
235000020681 well water Nutrition 0.000 description 1
239000002349 well water Substances 0.000 description 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G01N33/743—Steroid hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5089—Processes
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
- G01N33/5375—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody by changing the physical or chemical properties of the medium or immunochemicals, e.g. temperature, density, pH, partitioning
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F02—COMBUSTION ENGINES; HOT-GAS OR COMBUSTION-PRODUCT ENGINE PLANTS
- F02B—INTERNAL-COMBUSTION PISTON ENGINES; COMBUSTION ENGINES IN GENERAL
- F02B75/00—Other engines
- F02B75/02—Engines characterised by their cycles, e.g. six-stroke
- F02B2075/022—Engines characterised by their cycles, e.g. six-stroke having less than six strokes per cycle
- F02B2075/025—Engines characterised by their cycles, e.g. six-stroke having less than six strokes per cycle two

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Chemical & Material Sciences (AREA)
Urology & Nephrology (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Cell Biology (AREA)
Pathology (AREA)
Food Science & Technology (AREA)
Biotechnology (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Biochemistry (AREA)
Microbiology (AREA)
General Physics & Mathematics (AREA)
Endocrinology (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Investigating Or Analysing Biological Materials (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)

CH5723/79A 1978-06-20 1979-06-19 Verfahren zur bestimmung eines freien chemischen stoffes. CH647869A5 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US91736578A	1978-06-20	1978-06-20
US05/963,932 US4255411A (en)	1978-11-27	1978-11-27	Process of determining an immunogenic substance by competition with an antibody in a microcapsule

Publications (1)

Publication Number	Publication Date
CH647869A5 true CH647869A5 (de)	1985-02-15

Family

ID=27129721

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CH5723/79A CH647869A5 (de)	1978-06-20	1979-06-19	Verfahren zur bestimmung eines freien chemischen stoffes.

Country Status (9)

Country	Link
CA (1)	CA1120397A (da)
CH (1)	CH647869A5 (da)
DE (1)	DE2924881A1 (da)
DK (1)	DK256279A (da)
FR (1)	FR2432171A1 (da)
GB (1)	GB2023816B (da)
IT (1)	IT1119920B (da)
NO (1)	NO154409C (da)
SE (1)	SE445680B (da)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE8006102L (sv) *	1980-09-02	1982-03-03	Gambro Ab	Sett att utvinna en peptidinnehallande forening samt medel for genomforande av settet
EP0103605B1 (en) *	1982-03-19	1990-12-05	EKINS, Roger Philip	Method for free ligand assays
CA2105698A1 (en) *	1992-09-16	1994-03-17	Jozsef Hepp	Label trapping assay-nonseparation binding assay method

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3793445A (en) *	1970-04-29	1974-02-19	Wisconsin Alumni Res Found	Reagent for radioimmunoassay
US3896217A (en) *	1973-03-19	1975-07-22	Summa Corp	Method and apparatus for radioimmunoassay with regeneration of immunoadsorbent
US3925017A (en) *	1973-05-01	1975-12-09	Wisconsin Alumni Res Found	Preparation of dry, porous gel particles having high water regain for liquid sampling
US4061466A (en) *	1974-10-16	1977-12-06	Ingvar Gosta Holger Sjoholm	Biologically active composition and the use thereof

1979
- 1979-06-12 SE SE7905101A patent/SE445680B/sv not_active IP Right Cessation
- 1979-06-19 CH CH5723/79A patent/CH647869A5/de not_active IP Right Cessation
- 1979-06-19 NO NO792030A patent/NO154409C/no unknown
- 1979-06-19 CA CA000330134A patent/CA1120397A/en not_active Expired
- 1979-06-19 GB GB7921339A patent/GB2023816B/en not_active Expired
- 1979-06-19 IT IT68303/79A patent/IT1119920B/it active
- 1979-06-19 FR FR7915709A patent/FR2432171A1/fr active Granted
- 1979-06-19 DK DK256279A patent/DK256279A/da not_active Application Discontinuation
- 1979-06-20 DE DE19792924881 patent/DE2924881A1/de not_active Withdrawn

Also Published As

Publication number	Publication date
NO154409C (no)	1986-09-10
CA1120397A (en)	1982-03-23
DK256279A (da)	1980-01-28
FR2432171A1 (fr)	1980-02-22
NO792030L (no)	1979-12-21
GB2023816A (en)	1980-01-03
IT7968303A0 (it)	1979-06-19
FR2432171B1 (da)	1985-02-15
NO154409B (no)	1986-06-02
GB2023816B (en)	1983-02-23
SE7905101L (sv)	1979-12-21
SE445680B (sv)	1986-07-07
DE2924881A1 (de)	1980-01-17
IT1119920B (it)	1986-03-19

Publication	Publication Date	Title
DE3781335T2 (de)	1992-12-17	Immunoassay mit verwendung von kolloidalem gold.
DE2560554C2 (de)	1985-04-18	Verfahren zum Nachweisen und Bestimmen von Ak:Ag-Komplexen in einer biologischen Fluidprobe
DE2751588C3 (de)	1981-01-15	Verfahren zur Bestimmung eines Liganden oder der Liganden-Bindungskapazität in einem flüssigen Medium
DE3329728C2 (da)	1992-05-21
DE3685600T2 (de)	1993-01-21	Stabilisierte fluoreszierende seltenerd-indikatoren und physiologisch-reaktive kennsatz-spezies.
DE1648999C3 (de)	1975-09-04	Verfahren zur immunochemischen Bestimmung von Antigenen und Antikörpern
DE2421035A1 (de)	1974-11-21	Vorrichtung und verfahren zur durchfuehrung immunologischer bestimmungen
DE1517934A1 (de)	1970-03-12	Mit Molekularsieb ueberzogenes Adsorbens aus kleinen Teilchen und Verfahren mit dessen Anwendung
DE2936307A1 (de)	1980-04-10	Verfahren zur direkten bestimmung eines freien analyten in einer probe
DE2651139C3 (de)	1979-07-26	Reagens zur Durchführung eines Direktagglutinationstests zum Schwangerschaftsnachweis und Verfahren zu seiner Herstellung
EP0305337A1 (de)	1989-03-01	Verfahren zum Nachweis von Antigenen und/oder Antikörpern sowie Testausrüstung zur Durchführung des Verfahrens
DE2618386A1 (de)	1976-11-11	Verfahren zum nachweis biologischer teilchen
DE2633877A1 (de)	1977-03-10	Verfahren zur immunpruefung auf antigene in fester phase
DE69106002T2 (de)	1995-05-11	Testverfahren und reagenziensatz dafür.
DE2751589A1 (de)	1978-05-24	Verfahren zur bestimmung eines liganden oder der liganden-bindungskapazitaet in einem fluessigen medium
DE3784479T2 (de)	1993-06-17	Diagnostisches hilfsmittel, seine herstellung und seine verwendung.
DE2804657A1 (de)	1978-08-10	Verfahren und vorrichtung zur durchfuehrung von immuntests
DE2602068C2 (de)	1986-09-11	Reagens zur Unlöslichmachung eines Antigen/Antikörper-Komplexes
DE2419884A1 (de)	1974-10-31	Verfahren und vorrichtung zur bestimmung von trijodthyronin
DE2523207A1 (de)	1975-12-11	Verfahren zur bestimmung von antikoerpern
EP1064557B1 (de)	2004-05-06	Verfahren zum nachweis von antikörpern oder antigenen sowie zur blutgruppenbestimmung
DE60225788T2 (de)	2008-07-17	Immunreaktionsmessverfahren für die immunreaktionsmessung
DE2727206A1 (de)	1977-12-29	Verfahren zur bestimmung des saettigungsgrades des antikoerpers einer biologisch aktiven verbindung in einer biologischen fluessigkeit
CH647869A5 (de)	1985-02-15	Verfahren zur bestimmung eines freien chemischen stoffes.
DE68918286T2 (de)	1995-02-23	Verfahren zum testen einer immunologisch aktiven substanz und dafür geeignetes reagenz.

Legal Events

Date	Code	Title	Description
1985-06-14	PUE	Assignment	Owner name: DAMON BIOTECH, INC.
1989-02-28	PL	Patent ceased
2024-10-31	PL	Patent ceased